Search
Secnidazole
go.drugbank.com/drugs/DB12834ApprovedInvestigational[A245503] Secnidazole has been available in many other countries in Europe, Asia, South America, and Africa for decades. … Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent.
Mixtures: KADMIZOL®-F, GYNFLU® D TABLETASCategories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingTriclosan
go.drugbank.com/drugs/DB08604ApprovedAn aromatic ether that is phenol which is substituted at C-5 by a chloro group and at C-2 by a 2,4-dichlorophenoxy group. … It is widely used as a preservative and antimicrobial agent in personal care products such as soaps, skin creams, toothpaste and deodorants as well as in household items such as plastic chopping boards
Synonyms: 5-Chloro-2-(2,4-dichloro-phenoxy)-phenol, 2,4,4'-Trichloro-2'-hydroxydiphenyl etherMixtures: PREVENT 2 EN 1, KURSEPT %19 + %1 KREM (30 G)Tauroursodeoxycholic acid
go.drugbank.com/drugs/DB08834ApprovedInvestigationalWithdrawn[A249080] Tauroursodeoxycholic acid is currently used in Europe to treat and prevent gallstones as a bile acid derivative. … Tauroursodeoxycholic acid, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid [A249070] that is produced in humans at a low concentration.
Desvenlafaxine
go.drugbank.com/drugs/DB06700ApprovedInvestigational[L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe. … Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: O-desmethylvenlafaxineTrastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigationalTrastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers.
Categories: MATE 2 Substrates, P-glycoprotein substratesSynonyms: T-DXd, T- DXdZotepine
go.drugbank.com/drugs/DB09225ApprovedWithdrawn[A31855] It has been used as an antipsychotic in Japan, India and some places in Europe like UK and Germany since 1980's.[A31857] Zotepine was never approved by the FDA. … Zotepine, with the formula (2-chloro-11-(2-dimethyl-amino-ethoxy)-dibenzo thiepin, is a neuroleptic drug. It was designed and synthesized by Fujisawa Pharmaceutical Co Ltd.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 3-RingProducts: ZOLEPTIL © 50 MG TABLETAS RECUBIERTAS.Inotuzumab ozogamicin
go.drugbank.com/drugs/DB05889ApprovedInvestigational[A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). … Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, P-glycoprotein substratesProducts: BESPONSA 1 MG IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN TOZ, 1 ADETAbetimus
go.drugbank.com/drugs/DB06662InvestigationalAbetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.
Abaloparatide
go.drugbank.com/drugs/DB05084ApprovedInvestigational[L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized … [L740] It is a synthetic 34 amino acid peptide with 41% homology to human parathyroid hormone 1-34 and human PTHrP 1-34.
Lonapegsomatropin
go.drugbank.com/drugs/DB16220ApprovedInvestigationalLonapegsomatropin, also known as TransCon hGH or ACP 001, is a methoxypegylated prodrug of human growth hormone ([somatropin]) indicated for the treatment of children 1 year and older, weighing at least … [L36380] It was later approved by the European Commission on 13 January 2022.[L39900]
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 Inducers